Xeris Pharmaceuticals (XERS) AI Stock Analysis

• Market Cap: $1.59B
• Dividend Yield: N/A
• Average Volume (3M): 2.20M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.12
• Revenue Growth: 42.05%
• EPS Growth: 76.50%
• Country: US
• Employees: 394
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.00
• Shares Outstanding: 161,480,360
• 10 Day Avg. Volume: 2,116,415
• 30 Day Avg. Volume: 2,197,287
• PEG Ratio: 0.51
• Price to Book (P/B): -16.80
• Price to Sales (P/S): 2.45
• P/FCF Ratio: -13.15
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $12.33
• Price Target Upside: 35.79% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 51 Neutral
• Price Target: $7.50 ▼(-17.40% Downside)

Xeris Pharmaceuticals shows promising revenue growth and positive earnings call highlights, which are significant strengths. However, the company's financial performance is hindered by profitability and cash flow challenges, high leverage, and a negative equity position. The technical analysis suggests potential for a rebound, but valuation remains unattractive due to ongoing losses. Overall, the stock presents a mixed outlook with notable risks and opportunities.

Positive Factors

Revenue Growth

The strong revenue growth indicates robust demand for Xeris's products, suggesting effective market penetration and product acceptance, which is crucial for long-term sustainability.

Product Performance

RECORLEV's significant revenue growth underscores its market potential and strengthens Xeris's competitive position, supporting future expansion and profitability.

Cash Flow and Profitability

Achieving positive cash flow and net income marks a critical milestone, enhancing financial stability and enabling reinvestment in growth initiatives.

Negative Factors

High Leverage

High leverage and negative equity pose financial risks, limiting flexibility and increasing vulnerability to economic downturns, which could hinder long-term growth.

Profitability Challenges

Ongoing profitability challenges indicate cost structure inefficiencies, which could impact the company's ability to sustain growth and invest in new opportunities.

Cash Flow Management

Declining free cash flow growth highlights cash management issues, potentially affecting the company's ability to fund operations and strategic initiatives.

Xeris Pharmaceuticals Business Overview & Revenue Model

Company Description

Xeris Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with chronic diseases. The company specializes in the delivery of biologics and has developed a proprietary formulation technology that enables the stable, room-temperature storage of biologics, which helps improve patient compliance and convenience. Xeris's core products include Gvoke, an injectable glucagon for the treatment of severe hypoglycemia, and other potential therapies aimed at addressing unmet medical needs in diabetes and other chronic conditions.

How the Company Makes Money

Xeris Pharmaceuticals generates revenue primarily through the sales of its products, particularly Gvoke, which is marketed for the emergency treatment of severe hypoglycemia in patients with diabetes. The company also earns revenue through partnerships and collaborations with other pharmaceutical companies, which may include licensing agreements, milestone payments, and royalties from product sales. Additionally, Xeris may explore opportunities in research and development agreements that can provide further financial support through funding or shared revenues from new therapies developed using its proprietary technology.

Xeris Pharmaceuticals Financial Statement Overview

Summary

Xeris Pharmaceuticals is experiencing revenue growth but faces significant profitability and cash flow challenges. The high leverage and negative equity position present financial risks. While revenue is increasing, the company needs to address its cost structure and improve cash flow management to enhance financial health.

Income Statement

Xeris Pharmaceuticals has shown a positive revenue growth rate of 10.55% in the TTM, indicating a growing top line. However, the company is struggling with profitability, as evidenced by negative net profit and EBIT margins. The gross profit margin has decreased significantly from 81.86% in 2024 to 37.11% in the TTM, reflecting increased cost pressures or pricing challenges.

Balance Sheet

The balance sheet reveals high leverage with a negative equity position, resulting in a concerning debt-to-equity ratio of -13.32 in the TTM. The negative return on equity indicates that the company is not generating profits from its equity base, posing a risk to financial stability.

Cash Flow

Cash flow analysis shows a significant decline in free cash flow growth by -75.8% in the TTM, indicating cash management challenges. The operating cash flow to net income ratio is negative, suggesting inefficiencies in converting income into cash. However, the free cash flow to net income ratio is slightly above 1, indicating that free cash flow is covering net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2023	Dec 2023	Dec 2023
Income Statement
Total Revenue	266.14M	203.07M	163.91M	163.91M	163.91M	163.91M
Gross Profit	158.94M	166.24M	135.27M	135.27M	135.27M	135.27M
EBITDA	22.28M	-11.30M	-23.73M	-23.73M	-23.73M	-23.73M
Net Income	-15.64M	-54.84M	-62.26M	-62.26M	-62.26M	-62.26M
Balance Sheet
Total Assets	370.19M	323.06M	322.60M	322.60M	322.60M	322.60M
Cash, Cash Equivalents and Short-Term Investments	91.60M	71.62M	72.45M	72.45M	72.45M	72.45M
Total Debt	38.19M	271.45M	229.19M	229.19M	229.19M	229.19M
Total Liabilities	371.05M	352.68M	329.38M	329.38M	329.38M	329.38M
Stockholders Equity	-861.00K	-29.61M	-6.78M	-6.78M	-6.78M	-6.78M
Cash Flow
Free Cash Flow	19.82M	-37.85M	-49.29M	-49.29M	-49.29M	-49.29M
Operating Cash Flow	10.56M	-36.98M	-47.02M	-47.02M	-47.02M	-47.02M
Investing Cash Flow	9.65M	4.88M	-6.00M	-6.00M	-6.00M	-6.00M
Financing Cash Flow	12.05M	36.17M	-1.61M	-1.61M	-1.61M	-1.61M

Xeris Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 9.08
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XERS, the sentiment is Negative. The current price of 9.08 is below the 20-day moving average (MA) of 9.10, above the 50-day MA of 8.39, and above the 200-day MA of 5.76, indicating a neutral trend. The MACD of 0.12 indicates Positive momentum. The RSI at 31.22 is Neutral, neither overbought nor oversold. The STOCH value of 38.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for XERS.

Xeris Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
STOK	59 Neutral	$1.30B	34.05	15.02%	―	1128.17%	―
RCUS	56 Neutral	$2.44B	―	-68.13%	―	-8.75%	-8.79%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
XERS	51 Neutral	$1.59B	―	―	―	42.05%	76.50%
ZYME	48 Neutral	$1.37B	―	-19.89%	―	95.94%	35.69%
SNDX	48 Neutral	$1.31B	―	-129.32%	―	597.19%	0.45%
RAPP	44 Neutral	$1.21B	―	-23.41%	―	―	―

Xeris Pharmaceuticals Corporate Events

Xeris Biopharma Reports Strong Q3 2025 Financial Results

Xeris Biopharma Holdings, Inc. is a rapidly expanding biopharmaceutical company dedicated to enhancing patient lives through the development and commercialization of innovative therapeutic products. The company operates in the healthcare sector, with a focus on treatments for conditions such as endogenous Cushing’s syndrome, severe hypoglycemia, and primary periodic paralysis.

Xeris Biopharma Reports Record Revenue Growth in Earnings Call

Xeris Biopharma’s recent earnings call painted a picture of robust financial health and strategic optimism. The company reported record revenue growth, driven by strong product performance, particularly from RECORLEV. Despite facing increased expenses and potential competitive pressures, Xeris remains confident in its strategic growth plans and financial milestones, suggesting a positive outlook.

Xeris Pharmaceuticals Reports Record Revenue and Growth

Xeris Pharmaceuticals’ recent earnings call painted a picture of robust financial health and promising growth prospects. The company reported a record-breaking quarter with significant revenue growth and increased demand for its key products, particularly Recorlev. Despite some challenges, such as increased expenses and a slight decline in gross margin, the overall sentiment was positive, with raised revenue guidance and a favorable adjusted EBITDA.

Xeris Biopharma Reports Strong Q2 2025 Results

Xeris Biopharma Holdings, Inc., a biopharmaceutical company based in Chicago, focuses on developing and commercializing innovative therapies, including products like Recorlev, Gvoke, and Keveyis, with a robust pipeline of development programs.